Furthermore, our findings show that inhibition of the MAPK/ERK1,2 downstream signalling pathway with MEK1/2 inhibitor, trametinib, significantly reduced mROS levels in HSVSMCs from both non-diabetic (Figure 6B) and T2DM patients (Figure 6D). Here, MAPK3 is linked to type 2 diabetes mellitus.